Literature DB >> 8640445

Cell surface binding characteristics correlate with consensus type I interferon enhanced activity.

S B Klein1, L M Blatt, M W Taylor.   

Abstract

The binding characteristics of a genetically engineered consensus interferon with unusually high biologic activity were compared to the characteristics of recombinant interferon-alpha 2. Both interferon-alpha 2 and the consensus interferon produced typical biphasic Scatchard plots, indicating multiple independent binding sites. The consensus interferon, which exhibited a biologic potency more than 10-fold greater than all other type I interferons, also exhibited binding site affinities greater than those for IFN-alpha 2b. In addition, a larger number of high, and low-affinity cell surface sites were recognized by the consensus interferon, resulting in equivalent numbers of sites at reduced molar concentrations compared to IFN-a2b. Thus, at any given biologic activity, similar numbers of sites were bound by the consensus interferon and IFN-alpha 2, despite differences in their molar concentrations. No differences in internalization kinetics were identified between the two interferons, indicating that the differences in cell surface binding may be sufficient to produce the differences in biologic activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640445     DOI: 10.1089/jir.1996.16.1

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  4 in total

1.  Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C.

Authors:  Ying Huang; Jordan J Feld; Ronda K Sapp; Santosh Nanda; Jiing-Huey Lin; Lawrence M Blatt; Michael W Fried; Krishna Murthy; T Jake Liang
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

Review 2.  Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.

Authors:  E B Melian; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients.

Authors:  Samuel B Ho; Bashar Aqel; Eric Dieperink; Shanglei Liu; Lori Tetrick; Yngve Falck-Ytter; Charles DeComarmond; Coleman I Smith; Daniel P McKee; William Boyd; Clark C Kulig; Edmund J Bini; Marcos C Pedrosa
Journal:  Dig Dis Sci       Date:  2011-01-11       Impact factor: 3.199

Review 4.  Global virus outbreaks: Interferons as 1st responders.

Authors:  Ben X Wang; Eleanor N Fish
Journal:  Semin Immunol       Date:  2019-06       Impact factor: 11.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.